Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany.
作者信息
Morbach Caroline, Papagianni Aikaterini, Ihne-Schubert Sandra, Cejka Vladimir, Steinhardt Maximilian, Fette Georg, Held Melissa, Geier Andreas, Einsele Hermann, Frantz Stefan, Knop Stefan, Sommer Claudia, Störk Stefan
机构信息
Department Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University Hospital Würzburg, Am Schwarzenberg 15, 97078, Würzburg, Germany.
Department Medicine I, University Hospital Würzburg, Würzburg, Germany.
出版信息
Clin Res Cardiol. 2024 May;113(5):653-655. doi: 10.1007/s00392-023-02163-x. Epub 2023 Feb 23.
Abstract
摘要
相似文献
1
Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany.他法美明用于心脏转甲状腺素蛋白淀粉样变性：在德国真实临床环境中的应用
Clin Res Cardiol. 2024 May;113(5):653-655. doi: 10.1007/s00392-023-02163-x. Epub 2023 Feb 23.
2
A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.关于转甲状腺素蛋白心脏淀粉样变患者塔法米迪司给药的声明。
Circ J. 2019 Dec 25;84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16.
3
[Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].[心脏转甲状腺素蛋白淀粉样变性的诊断与治疗。使用氯苯唑酸的创新疗法。]
Rev Med Liege. 2022 Jan;77(1):63-68.
4
Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.塔非酰胺治疗遗传性转甲状腺素蛋白淀粉样变心肌病：一例报告
Cardiology. 2017;137(2):74-77. doi: 10.1159/000455089. Epub 2017 Feb 3.
5
Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.塔非酰胺：一种用于治疗野生型转甲状腺素蛋白淀粉样变性和遗传性转甲状腺素蛋白淀粉样变性心肌病的选择性转甲状腺素蛋白稳定剂。
Drugs Today (Barc). 2019 Dec;55(12):727-734. doi: 10.1358/dot.2019.55.12.3078389.
6
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.用塔法米迪治疗转甲状腺素蛋白淀粉样心肌病患者的长期生存。
Circ Heart Fail. 2022 Jan;15(1):e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193. Epub 2021 Dec 20.
7
Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis.了解转甲状腺素蛋白心脏淀粉样变性患者转甲状腺素蛋白稳定后功能能力的变化。
Circ Heart Fail. 2022 Jul;15(7):e009387. doi: 10.1161/CIRCHEARTFAILURE.122.009387. Epub 2022 Jun 29.
8
Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.他司美格鲁肽：转甲状腺素蛋白淀粉样变心肌病的首个一流转甲状腺素蛋白稳定剂。
Ann Pharmacother. 2020 May;54(5):470-477. doi: 10.1177/1060028019888489. Epub 2019 Nov 18.
9
Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.监测转甲状腺素蛋白淀粉样变心肌病中 Tafamidis 治疗反应的系列天然 T1 和细胞外容积。
ESC Heart Fail. 2019 Feb;6(1):232-236. doi: 10.1002/ehf2.12382. Epub 2018 Nov 27.
10
Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.塔非酰胺在转甲状腺素蛋白淀粉样心肌病中的作用：对转甲状腺素蛋白稳定性及临床结局的影响
Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.
引用本文的文献
1
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy.转甲状腺素蛋白淀粉样心肌病当代长期使用他法米地斯治疗效果的多中心研究。
JACC CardioOncol. 2025 Apr;7(3):282-293. doi: 10.1016/j.jaccao.2024.12.005. Epub 2025 Feb 11.
2
Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study.心脏转甲状腺素蛋白淀粉样变性的真实世界特征与治疗：一项多中心观察性研究。
ESC Heart Fail. 2025 Apr;12(2):1203-1216. doi: 10.1002/ehf2.15126. Epub 2024 Nov 6.
3
Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment.对开始使用塔非酰胺治疗的野生型转甲状腺素蛋白淀粉样心肌病当代患者疾病进展的多参数监测
J Clin Med. 2024 Jan 4;13(1):284. doi: 10.3390/jcm13010284.
本文引用的文献
1
Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.基于心血管磁共振成像（CMR）的野生型转甲状腺素蛋白淀粉样变心肌病（ATTRwt）患者用塔法米迪治疗的价值。
Clin Res Cardiol. 2023 Mar;112(3):353-362. doi: 10.1007/s00392-022-02035-w. Epub 2022 Jun 6.
2
Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.特发性淀粉样变心肌病患者用塔法米迪治疗可延迟左心室结构和功能的改变。
Eur Heart J Cardiovasc Imaging. 2022 Jun 1;23(6):767-780. doi: 10.1093/ehjci/jeab226.
3
Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).心脏淀粉样变性的诊断和治疗：德国心脏病学会（DGK）立场声明。
Clin Res Cardiol. 2021 Apr;110(4):479-506. doi: 10.1007/s00392-020-01799-3. Epub 2021 Jan 18.
4
Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.淀粉样变性——一种被低估的疾病的诊断与治疗。
Dtsch Arztebl Int. 2020 Mar 6;117(10):159-166. doi: 10.3238/arztebl.2020.0159.
5
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
6
Exporting Data from a Clinical Data Warehouse.从临床数据仓库导出数据。
Stud Health Technol Inform. 2018;248:88-93.
Zotero 插件